Analysts Expect ADMA Biologics, Inc. (NASDAQ:ADMA) to Post -$0.15 EPS

Analysts expect that ADMA Biologics, Inc. (NASDAQ:ADMA) will report earnings of ($0.15) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for ADMA Biologics’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.12). ADMA Biologics reported earnings of ($0.23) per share in the same quarter last year, which would suggest a positive year over year growth rate of 34.8%. The firm is scheduled to announce its next earnings results on Wednesday, August 4th.

On average, analysts expect that ADMA Biologics will report full-year earnings of ($0.57) per share for the current financial year, with EPS estimates ranging from ($0.66) to ($0.46). For the next fiscal year, analysts forecast that the business will report earnings of ($0.34) per share, with EPS estimates ranging from ($0.45) to ($0.22). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Tuesday, May 11th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The business had revenue of $16.05 million during the quarter, compared to analysts’ expectations of $15.63 million. ADMA Biologics had a negative net margin of 155.78% and a negative return on equity of 85.82%.

ADMA has been the subject of several research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 price objective on shares of ADMA Biologics in a research note on Monday, April 5th. HC Wainwright dropped their price objective on shares of ADMA Biologics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, July 6th. Maxim Group reissued a “buy” rating and issued a $6.00 price target on shares of ADMA Biologics in a research note on Friday, March 26th. Zacks Investment Research cut shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 13th. Finally, Raymond James dropped their price target on shares of ADMA Biologics from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Friday, March 26th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $6.33.

A number of institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. increased its position in shares of ADMA Biologics by 7.4% in the 1st quarter. Principal Financial Group Inc. now owns 360,511 shares of the biotechnology company’s stock valued at $634,000 after purchasing an additional 24,953 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of ADMA Biologics by 370.4% in the 1st quarter. Squarepoint Ops LLC now owns 575,325 shares of the biotechnology company’s stock valued at $1,013,000 after purchasing an additional 453,024 shares during the last quarter. Morgan Stanley increased its position in shares of ADMA Biologics by 85.0% in the 1st quarter. Morgan Stanley now owns 380,576 shares of the biotechnology company’s stock valued at $670,000 after purchasing an additional 174,852 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $76,000. Finally, Jane Street Group LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $40,000. Institutional investors own 37.72% of the company’s stock.

ADMA stock opened at $1.59 on Monday. The stock’s 50-day moving average is $1.67. The company has a debt-to-equity ratio of 0.89, a current ratio of 8.36 and a quick ratio of 3.92. ADMA Biologics has a 52 week low of $1.38 and a 52 week high of $4.20.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Article: Special Dividends

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.